Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
STXS 
Stereotaxis Inc (STXS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: STXS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -72.07% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 147.03M USD | Price to earnings Ratio - | 1Y Target Price 4.5 |
Price to earnings Ratio - | 1Y Target Price 4.5 | ||
Volume (30-day avg) 623686 | Beta 1.54 | 52 Weeks Range 1.66 - 3.29 | Updated Date 04/1/2025 |
52 Weeks Range 1.66 - 3.29 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.3 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-03-03 | When Before Market | Estimate -0.065 | Actual -0.09 |
Profitability
Profit Margin -89.33% | Operating Margin (TTM) -101.23% |
Management Effectiveness
Return on Assets (TTM) -31.72% | Return on Equity (TTM) -144.19% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 146166222 | Price to Sales(TTM) 5.46 |
Enterprise Value 146166222 | Price to Sales(TTM) 5.46 | ||
Enterprise Value to Revenue 5.43 | Enterprise Value to EBITDA -10.06 | Shares Outstanding 85979696 | Shares Floating 59121335 |
Shares Outstanding 85979696 | Shares Floating 59121335 | ||
Percent Insiders 15.41 | Percent Institutions 48.83 |
Analyst Ratings
Rating 4.5 | Target Price 4.5 | Buy 2 | Strong Buy 2 |
Buy 2 | Strong Buy 2 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Stereotaxis Inc
Company Overview
History and Background
Stereotaxis Inc. was founded in 2001. It focuses on robotic magnetic navigation for minimally invasive surgery. The company has evolved from initial research to commercialization of its robotic systems used in cardiac and neurovascular procedures.
Core Business Areas
- Robotic Magnetic Navigation (RMN) Systems: Stereotaxis designs, manufactures, and markets robotic systems for minimally invasive surgery. These systems enhance the precision and safety of interventional procedures.
- Disposables: Stereotaxis sells disposable products used in conjunction with its RMN systems, providing a recurring revenue stream.
- Service and Support: Stereotaxis offers service and support to customers who have purchased its RMN systems.
Leadership and Structure
David Fischel is the Chairman and CEO. The company has a functional organizational structure with departments for engineering, sales, marketing, and finance.
Top Products and Market Share
Key Offerings
- Genesis RMN System: The Genesis RMN System is Stereotaxis' flagship product, used to perform minimally invasive cardiac ablation procedures. Market share data is difficult to ascertain with precision but estimates position Stereotaxis as a significant player in the robotic cardiac ablation market, particularly for complex arrhythmias. Competitors include Johnson & Johnson (Biosense Webster), Abbott, and Boston Scientific, which offer competing catheter navigation systems and ablation technologies.
- Niobe ES RMN System: The NIOBE ES system allows doctors to perform complex cardiac procedures with accuracy and increased safety by controlling the magnetic navigation systems. Competition includes Biosense Webster's CARTO system, Abbott's EnSite Precision system, and Boston Scientific's Rhythmia HDx mapping system. Market share is smaller than Genesis RMN system.
Market Dynamics
Industry Overview
The medical robotics industry is growing, driven by demand for minimally invasive procedures, increased precision, and improved patient outcomes. The market is competitive, with established medical device companies and emerging technology providers.
Positioning
Stereotaxis is positioned as an innovator in robotic magnetic navigation. Its competitive advantage lies in its unique RMN technology, which offers precise and stable catheter control.
Total Addressable Market (TAM)
The TAM for robotic cardiac ablation is estimated to be in the billions of dollars. Stereotaxis is positioned to capture a portion of this market with its RMN technology.
Upturn SWOT Analysis
Strengths
- Proprietary RMN technology
- Precise and stable catheter control
- Minimally invasive procedure capabilities
- Experienced leadership team
Weaknesses
- Limited market penetration
- High capital costs for systems
- Dependence on specialized expertise
- Relatively small company size compared to competitors
Opportunities
- Expanding into new geographical markets
- Developing new applications for RMN technology
- Partnering with hospitals and research institutions
- Capitalizing on the increasing demand for minimally invasive procedures
Threats
- Competition from established medical device companies
- Technological advancements by competitors
- Regulatory hurdles
- Economic downturn affecting hospital budgets
Competitors and Market Share
Key Competitors
- JNJ
- ABT
- BSX
Competitive Landscape
Stereotaxis' RMN technology offers unique advantages in precision and stability, but it faces intense competition from established medical device companies with larger market shares and broader product portfolios.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Growth has been dependent on new system installations and disposable sales. The adoption rate has been slower than initially anticipated.
Future Projections: Analyst estimates for Stereotaxis' future growth vary, depending on factors such as RMN system adoption and market penetration. Consult financial data providers for analyst estimates.
Recent Initiatives: Recent initiatives include the development of new RMN system features, expansion into new clinical applications, and strategic partnerships with hospitals and research institutions.
Summary
Stereotaxis has an innovative RMN system that provides surgeons with precise control, which is not seen in other systems. However, adoption has been slower than expected. The company faces stiff competition from bigger players in the medical device industry with much larger customer bases and revenue. Stereotaxis needs to work hard to expand into new clinical apps and secure more partnerships. The company should watch out for any new, cheaper, easier, and better technologies that become more mainstream.
Similar Companies
ABT
Abbott Laboratories
ABT
Abbott Laboratories
BSX
Boston Scientific Corp
BSX
Boston Scientific Corp
JNJ
Johnson & Johnson
JNJ
Johnson & Johnson
SIFI
Harbor Scientific Alpha Income
SIFI
Harbor Scientific Alpha Income
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Industry Reports
- Analyst Reports
- Company Website
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It should not be considered financial advice. Market share data is estimated and may not be precise. This is not a recommendation to buy or sell stock.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Stereotaxis Inc
Exchange NYSE MKT | Headquaters Saint Louis, MO, United States | ||
IPO Launch date 2004-08-12 | CEO & Chairman Dr. David Leo Fischel C.A.I.A., C.F.A., C.P.A., M.B.A. | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 139 | Website https://www.stereotaxis.com |
Full time employees 139 | Website https://www.stereotaxis.com | ||
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. The company offers robotic magnetic navigation (RMN) systems, such as the Genesis RMN, which enable physicians to complete interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites; and GenesisX RMN, which is designed to enhance the accessibility of RMN by eliminating the lengthy construction cycle necessary to install prior generation RMN systems. It also offers Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and x-ray systems. In addition, the company offers disposables and other accessories, including QuikCAS, an automated catheter advancement single-use disposable device; iCONNECT; V-CAS; and MAGiC catheter for cardiac ablation procedures. Further, it provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. It markets its products through direct sales force, distributors, and sales agents. Stereotaxis, Inc. was incorporated in 1990 and is based in Saint Louis, Missouri.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.